{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-22-021835","form_type":"8-K","ticker":"PULM","cik":"0001574235","company_name":"Pulmatrix, Inc.","filed_at":"2022-08-10T23:59:59+00:00","discovered_at":"2026-05-14T18:03:56.219668+00:00","generated_at":"2026-06-24T01:25:13.282520+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Pulmatrix Q2 revenue falls 41% to $1.3M; net loss widens to $4.6M; cash $42.9M","bullets":["Q2 2022 revenue $1.3M vs $2.2M in Q2 2021; decrease driven by no PUR1800 revenue offset by Cipla agreement for Pulmazole.","Net loss of $4.6M ($1.36 per share) vs $3.9M ($1.37) in Q2 2021; wider loss on lower revenue.","Cash and equivalents $42.9M at June 30, 2022; expects to fund operations into Q2 2024.","PUR3100 Phase 1 study dosed 23 of 24 patients; top-line data expected Q4 2022.","Pulmazole Phase 2b study start-up initiated; patient dosing on track for Q1 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-22-021835","json":"https://secwatch.observer/filing/0001493152-22-021835.json","markdown":"https://secwatch.observer/filing/0001493152-22-021835.md","text":"https://secwatch.observer/filing/0001493152-22-021835.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1574235/000149315222021835/0001493152-22-021835-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1574235/000149315222021835/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-24T01:25:13.282520+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}